An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 [ortataxel] in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2007
At a glance
- Drugs Ortataxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Oct 2007 Status changed from in progress to completed.
- 29 Sep 2005 New trial record.